NOKOMIS, Fla.--(BUSINESS WIRE)--Rainbow BioSciences, LLC, the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC), announced today that its current joint venture target, Amarantus BioSciences, Inc., has achieved positive results in a pre-clinical experiment demonstrating the potential of its new Parkinson’s disease therapy currently in development.
